Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline

Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Update on POLB 001 Clinical Development
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Results of the proposal to purchase shares from Distribution in Specie shareholders
Continued expansion of the POLB 002 patent family following European Patent Office approval
Proposal to Purchase Shares from Distribution in Specie Shareholders
On track to commence LPS human challenge clinical trial in June 2022
Poolbeg Pharma commences trading on OTCQB Market in the United States
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Poolbeg makes excellent progress post IPO and momentum building